News articles about PerkinElmer (NYSE:PKI) have trended somewhat positive on Saturday, according to Alpha One Sentiment. The research group, a division of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PerkinElmer earned a news impact score of 0.22 on Alpha One’s scale. Alpha One also assigned press coverage about the medical research company an impact score of 75 out of 100, meaning that recent news coverage is likely to have an impact on the company’s share price in the immediate future.
PerkinElmer (NYSE:PKI) opened at 63.57 on Friday. The company has a 50 day moving average of $62.63 and a 200 day moving average of $56.70. The company has a market capitalization of $7.00 billion, a PE ratio of 30.99 and a beta of 0.73. PerkinElmer has a 1-year low of $45.35 and a 1-year high of $65.35.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.01. PerkinElmer had a return on equity of 13.97% and a net margin of 10.24%. The company had revenue of $514.12 million during the quarter, compared to the consensus estimate of $506.81 million. During the same quarter in the prior year, the company earned $0.50 EPS. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, analysts predict that PerkinElmer will post $2.86 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 10th. Shareholders of record on Friday, July 21st will be issued a $0.07 dividend. The ex-dividend date of this dividend is Wednesday, July 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.44%. PerkinElmer’s payout ratio is currently 13.66%.
PKI has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed a “hold” rating and set a $65.00 price objective on shares of PerkinElmer in a report on Monday, May 15th. Barclays PLC set a $55.00 price objective on shares of PerkinElmer and gave the stock a “sell” rating in a report on Saturday, May 6th. Jefferies Group LLC reiterated a “hold” rating and set a $49.00 target price on shares of PerkinElmer in a research note on Friday, May 5th. Citigroup Inc. upped their target price on shares of PerkinElmer from $57.00 to $67.00 and gave the company a “buy” rating in a research note on Friday, April 7th. Finally, BidaskClub cut shares of PerkinElmer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $57.30.
In other PerkinElmer news, insider Robert F. Friel sold 124,837 shares of PerkinElmer stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $60.11, for a total value of $7,503,952.07. Following the transaction, the insider now directly owns 696,810 shares of the company’s stock, valued at approximately $41,885,249.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Okun sold 3,000 shares of PerkinElmer stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $57.27, for a total value of $171,810.00. Following the completion of the sale, the insider now owns 12,441 shares in the company, valued at $712,496.07. The disclosure for this sale can be found here. In the last ninety days, insiders sold 169,565 shares of company stock worth $10,228,809. Insiders own 2.20% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.